Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer |
| June 25, 2018 | June 2018 Bond Updates |
|
CAMBRIDGE, Mass., June 25, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced top-line results from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141... |
| View more at: https://www.prnewswire.com/news-releases/merrimack-announces-top-line-results-from-randomized-phase-2-trial-of-mm-141-in-front-line-metastatic-pancreatic-cancer-300671289.html |
| Related News |
|